Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

3.82

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.8

Max

3.92

Chiffres clés
By Trading Economics
Revenu	-42M -78M
BPA	-0.59
Employés	106
EBITDA	-42M -77M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+129.95% upside

Dividendes
By Acuity
Prochains Résultats	6 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	20M 351M
Ouverture précédente	3.82
Clôture précédente	3.82

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 août 2026, 23:56 UTC

Mettler-Toledo shares are higher in after-market trading, reflecting a broader market rebound amid gains from major stocks like Tesla and UnitedHealth.

21 août 2026, 23:56 UTC

Constellation Energy shares are higher in after-market hours, reflecting broader gains among major stocks. No specific news was identified for the price movement.

21 août 2026, 23:56 UTC

Virtu Financial Inc. shares are higher in after-market trading, following a broader market rebound despite earlier pressures from rising crude oil prices and bond yields.

21 août 2026, 23:56 UTC

TE Connectivity Ltd. shares declined in after-market trading, remaining near the lower end of their one-month range and below the 20-day moving average.

21 août 2026, 23:56 UTC

APA Corp. is trading higher in after-market hours, reflecting broader market strength despite a recent yield-driven selloff. No specific news was identified.

21 août 2026, 23:56 UTC

Social Media

Options trading for Costco includes a notable $950 call option that rose from $0.99 to $2.70. Shares remain roughly flat in after-market trading.

21 août 2026, 23:56 UTC

MercadoLibre Inc. is higher in after-market hours, reflecting routine performance amid broader market gains following earlier pressure from rising crude oil prices and bond yields.

21 août 2026, 23:56 UTC

NiSource shares are higher in after-market trading, reflecting broader market gains following a recent selloff. No specific company news was identified.

21 août 2026, 23:56 UTC

OPKO Health Inc. shares declined in after-market trading, despite gains in major stocks as the broader market rebounded from earlier pressures.

21 août 2026, 23:56 UTC

Agilent Technologies Inc shares are lower in after-market hours, diverging from broader market gains. No specific news was identified to explain the decline.

21 août 2026, 23:56 UTC

Devon Energy Corp shows little change in after-market trading, remaining near unchanged since Friday's close and positioned 8.63% above its 20-day moving average.

21 août 2026, 23:56 UTC

Ginkgo Bioworks Holdings Inc is higher in after-market trading amid a broader market rebound, despite no specific company news identified.

21 août 2026, 23:56 UTC

Equitable Holdings Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

21 août 2026, 23:56 UTC

Correlated Moves

US Bancorp shares are higher in after-hours trading, reflecting positive sentiment in the banking sector amid a broader market rebound.

21 août 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

21 août 2026, 23:56 UTC

Macro News

ETF Constituents

Vanguard Information Technology ETF rises in after-market hours, supported by gains in key holdings like NVIDIA, Apple, and Intuit amid broader market recovery.

21 août 2026, 23:56 UTC

Century Aluminum Co. shares gained after-market, recovering from an earlier dip. The movement reflects broader market trends amid rising crude oil prices and bond yields.

21 août 2026, 23:56 UTC

Correlated Moves

Duke Energy shares rose in after-market trading, reflecting broader market gains despite remaining below the 20-day moving average after four consecutive lower sessions.

21 août 2026, 23:56 UTC

B&G Foods Inc. traded roughly flat during after-market hours with no specific news. The broader market rebounded, but the stock remains near its one-month low.

21 août 2026, 23:52 UTC

South Africa's Balance of Trade Report on August 28, 2026: Analysts Anticipate Continued Surplus Amid Global Economic Instability.

21 août 2026, 23:52 UTC

S&P/Case-Shiller Home Price Index Release on August 25, 2026, Expected to Show Modest Growth Amid Mixed Housing Market Sentiment and Rising Inflation Concerns.

21 août 2026, 23:52 UTC

US GDP Price Index QoQ 2nd Estimate for Q2, forecasted at a 0.063% increase, set to release on August 26 amid rising optimism in economic indicators and inflation concerns.

21 août 2026, 23:52 UTC

XRP is trading higher during Friday's session, supported by a broader cryptocurrency rally and a U.S. Treasury announcement on bond buyback operations.

21 août 2026, 23:51 UTC

Shares of Science Applications International Corp. are lower in after-market trading, reflecting a notable retracement despite being above the 20-day moving average.

21 août 2026, 23:51 UTC

Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.

21 août 2026, 23:51 UTC

Par Pacific Holdings Inc. shares are lower in after-market hours, continuing a trend within the broader context of its one-month trading range.

21 août 2026, 23:51 UTC

Paylocity Holding Corp shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

21 août 2026, 23:51 UTC

Shift4 Payments Inc is trading higher in after-market hours, supported by a rally in cryptocurrencies that benefits crypto-exposed equities.

21 août 2026, 23:51 UTC

Coca-Cola Europacific Partners PLC shares are higher in after-market hours, recovering from an earlier dip amid broader market trends and a cryptocurrency rally.

21 août 2026, 23:51 UTC

Kirby Corp shares are higher in after-market trading, reflecting a strong performance that exceeds the 20-day moving average. No specific news was identified.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

129.95% hausse

Prévisions sur 12 Mois

Moyen 8.83 USD 129.95%

Haut 11 USD

Bas 5 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.